Special 12/2012

  • BIO-Regions in the European Union

    In an era of tight purse-strings when it comes to collecting capital for long-term projects like drug development, the concentration of know-how in a biotech cluster, incubator or meta-cluster offers bio­tech companies many advantages. Access to a common infrastructure and networks, better visibility for potential corporate and VC investors, and improved access to public funding are only a few of them. Well­­-established biotech hubs also exert an irresistible appeal to national and EU policymakers. They of course are seeking to create high-paying jobs, attract new companies as well as investors and stimulate the socioeconomic growth of entire regions (see p. 38). In this special, EuroBio­techNews presents some of the strategies that European bio-incubators are implementing in their quests to become the next major global hub.

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/spezial/2012/12/pos/1.html?cHash=2aa63e7a3c47f54d547eeaaa494e591b&sort=asc

Kurszettel

Alle Kurse

TOP

  • WILEX2.40 EUR6.67%
  • SANTHERA100.10 CHF1.78%
  • ACTELION112.70 CHF1.35%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • VITA 343.70 EUR-5.85%
  • EVOTEC3.68 EUR-1.60%

TOP

  • SANTHERA100.10 CHF67.1%
  • BB BIOTECH142.65 EUR10.2%
  • MAGFORCE6.80 EUR6.1%

FLOP

  • MOLOGEN7.31 EUR-14.0%
  • THERAMETRICS0.07 CHF-12.5%
  • VITA 343.70 EUR-11.1%

TOP

  • SANTHERA100.10 CHF4290.4%
  • CO.DON2.51 EUR191.9%
  • PAION2.43 EUR164.1%

FLOP

  • CYTOS0.25 CHF-93.9%
  • MEDIGENE4.53 EUR-69.2%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 01.09.2014